Two medicines, side by side
Indapamide vs furosemide
Indapamide and furosemide are both labeled for high blood pressure, heart failure and edema (fluid retention). Drugs@FDA records approvals of indapamide since 1983 and of furosemide since 1966. Pharmacies paid $0.109 per indapamide 1.25 mg tablet and $0.490 per mL (Furosemide 20 mg/2 mL vial) (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, indapamide is a thiazide-like diuretic and furosemide a loop diuretic.
Check it at the source: the indapamide FDA label on DailyMed (effective October 1, 2022); the furosemide FDA label on DailyMed (effective September 30, 2025).
Highlights of the indapamide record
Indapamide (Lozol) · label of October 1, 2022
Used for
From the label: indicationsIndapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard (see PRECAUTIONS ). […]
On the market
- Earliest approval on file
- July 6, 1983
- Generic labelers
- 8 labelers
- Pharmacy cost
- $0.109 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the furosemide record
Furosemide (Lasix) · label of September 30, 2025
Used for
From the label: indicationsEdema LASIX is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. LASIX is particularly useful when an agent with greater diuretic potential is desired. […]
On the market
- Earliest approval on file
- July 1, 1966
- Generic labelers
- 52 labelers
- Pharmacy cost
- $0.490 per mL
Supply and safety
- Shortage
- In shortage
- Recalls
- 8
Source: FDA drug labels via openFDA (Indapamide label of October 1, 2022, Furosemide label of September 30, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do indapamide and furosemide differ on the record?
In FDA's classes, indapamide is a thiazide-like diuretic and furosemide a loop diuretic.
Half-life, in each label's words: Indapamide, “The half-life of indapamide in whole blood is approximately 14 hours.”; Furosemide, “The terminal half-life of furosemide is approximately 2 hours.”
Generics: indapamide since 1995; furosemide since 1985 (Drugs@FDA).
| Indapamide | Furosemide | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure, Edema (fluid retention) | Heart failure, High blood pressure, Edema (fluid retention) |
| Pharmacologic class | Thiazide-like Diuretic | Loop Diuretic |
| How it works (label) | n/a | n/a |
| Half-life (label) | The half-life of indapamide in whole blood is approximately 14 hours. | The terminal half-life of furosemide is approximately 2 hours. |
| Earliest approval on file (Drugs@FDA) | July 6, 1983 | July 1, 1966 |
| First generic approved | July 27, 1995 | September 26, 1985 |
| Generic labelers (NDC) | 8 labelers | 52 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.109 per tablet (Indapamide 1.25 mg tablet) | $0.490 per mL (Furosemide 20 mg/2 mL vial) |
| 12-month price change | +9% | +31% |
| Boxed warning | No | No |
| Shortage now | No current entry | In shortage |
| Recalls recorded | 0 | 8 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 17,817 | 398,354 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to indapamide
- every medicine labeled for the same conditions